In this e-learning course, five important aspects of use of GLP-1RAs are discussed. Member registration (free) is needed to enroll in this course.

5 Things a cardiologist needs to know about GLP-1 RA Prof. Deanfield discusses the changing paradigm for managing cardiometabolic risk in clinical practice by the emergence of diabetes. He states that GLP-1 receptor agonists will be an important component of treatment strategies.

5 Things a cardiologist needs to know about GLP-1RA Prof. Verma discusses the CV results of clinical trials with GLP-1RAs and how these translate to CV protection in T2DM.

5 Things a cardiologist needs to know about GLP-1RA First, prof. Montanya describes the US and European recommendations for the use of GLP-1RA in T2DM patients, and then discusses when to initiate GLP-1RA in patients with high CV risk or clinical ASCVD, CKD, or HF, or in those with low CV risk.

5 Things a cardiologist needs to know about GLP-1RA Prof. Sattar describes the mechanism of action of GLP-1RAs and provides potential explanations for the cardiovascular benefit observed with these drugs.

5 Things a cardiologist needs to know about GLP-1RA Prof. Jacob discusses the shift in management of diabetes by a glycemic approach towards prevention of CV complications. He describes the evolution of the treatment recommendations in T2DM management.